Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Multimodal functional imaging for early response assessment in GIST patients treated with imatinib.

Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L, Seierstad T.

Acta Oncol. 2014 Jan;53(1):143-8. doi: 10.3109/0284186X.2013.798428. Epub 2013 May 28. No abstract available.

2.

Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.

Valls-Ferrusola E, García-Garzón JR, Ponce-López A, Soler-Peter M, Fuertes-Cabero S, Moragas-Solanes M, Riera-Gil E, Carrió-Gasset I, Lomeña-Caballero F.

Rev Esp Enferm Dig. 2012 Jul;104(7):360-6.

3.

Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.

Abhyankar SA, Nair N.

Clin Nucl Med. 2008 Mar;33(3):213-4. doi: 10.1097/RLU.0b013e318162db8d. No abstract available.

PMID:
18287851
4.

The use of contrast-enhanced ultrasound in patients with GIST metastases that are negative in CT and PET.

Dietrich C, Hartung E, Ignee A.

Ultraschall Med. 2008 Dec;29 Suppl 5:276-7. doi: 10.1055/s-2008-1027878. Epub 2009 Jan 28. No abstract available.

PMID:
19177288
5.

[Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors].

Simó Perdigó M, García Garzón JR, Soler Peter M, Pérez Moure G, López Gandul S, Lomeña Caballero FJ.

Rev Esp Med Nucl. 2006 Mar-Apr;25(2):80-8. Spanish.

PMID:
16759613
6.

Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.

Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H.

Anticancer Res. 2005 Nov-Dec;25(6C):4591-4.

7.

Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.

Shankar S, Dundamadappa SK, Karam AR, Stay RM, van Sonnenberg E.

Acta Radiol. 2009 Oct;50(8):837-44. doi: 10.1080/02841850903059423. Review.

PMID:
19735005
8.

Resistance to treatment in gastrointestinal stromal tumours: what radiologists should know.

Tirumani SH, Jagannathan JP, Hornick JL, Ramaiya NH.

Clin Radiol. 2013 Aug;68(8):e429-37. doi: 10.1016/j.crad.2013.03.016. Epub 2013 Apr 25. Review.

PMID:
23622797
9.

CT evaluation of gastrointestinal stromal tumors treated with imatinib mesylate.

Erturk SM.

AJR Am J Roentgenol. 2005 Nov;185(5):1366; author reply 1366-7. No abstract available.

PMID:
16247167
10.
11.

Primary GIST of the liver masquerading as primary intra-abdominal tumour: a rare extra-gastrointestinal stromal tumour (EGIST) of the liver.

Louis AR, Singh S, Gupta SK, Sharma A.

J Gastrointest Cancer. 2014 Sep;45(3):392-4. doi: 10.1007/s12029-013-9514-6. No abstract available.

PMID:
23749608
12.

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.

Shen C, Chen H, Yin Y, Chen J, Zhang B, Chen Z, Chen J.

Clinics (Sao Paulo). 2014 Nov;69(11):758-62. doi: 10.6061/clinics/2014(11)09.

13.

Esophageal gastrointestinal stromal tumor: report of 7 patients.

Shinagare AB, Zukotynski KA, Krajewski KM, Jagannathan JP, Butrynski J, Hornick JL, Ramaiya NH.

Cancer Imaging. 2012 Apr 27;12:100-8. doi: 10.1102/1470-7330.2012.0017.

14.

Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.

Gasparotto D, Miolo G, Torrisi E, Canzonieri V, Bertola G, Libra M, Marzotto A, Maestro R, Buonadonna A.

Int J Colorectal Dis. 2014 May;29(5):639-40. doi: 10.1007/s00384-014-1838-6. Epub 2014 Feb 15. No abstract available.

PMID:
24525699
15.
16.

[Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors].

García-González J, Sánchez Salmón A, Areses Manrique C, León Mateos L, Barandela Salgado J, López López R.

Rev Esp Med Nucl. 2007 Mar-Apr;26(2):100-2. Spanish.

PMID:
17386236
17.

Gastrointestinal stromal tumor with metastases in an adult woman treated with imatinib mesylate: MDCT findings.

Busalacchi PJ Sr, de la Calle MA, Torroba A, Del Río ST.

AJR Am J Roentgenol. 2005 Mar;184(3 Suppl):S58-61. No abstract available.

PMID:
15728023
18.

Response evaluation of gastrointestinal stromal tumors.

Choi H.

Oncologist. 2008;13 Suppl 2:4-7. doi: 10.1634/theoncologist.13-S2-4. Review.

19.

[18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].

Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla JF, Sainz-Esteban A, Barragán J, Portilla-Quattrociocchi H, Carril JM.

Rev Esp Med Nucl. 2008 May-Jun;27(3):168-75. Spanish.

PMID:
18570858
20.

Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.

Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T.

Digestion. 2013;87(1):47-52. doi: 10.1159/000343938. Epub 2013 Jan 21.

Supplemental Content

Support Center